Compare OLED & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | LEGN |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.9B |
| IPO Year | 1992 | 2020 |
| Metric | OLED | LEGN |
|---|---|---|
| Price | $118.73 | $22.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $181.33 | $69.58 |
| AVG Volume (30 Days) | 557.8K | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.64 | N/A |
| Revenue | $639,977,000.00 | ★ $909,045,000.00 |
| Revenue This Year | $2.50 | $68.83 |
| Revenue Next Year | $10.90 | $51.27 |
| P/E Ratio | $25.20 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $103.70 | $21.19 |
| 52 Week High | $164.29 | $45.30 |
| Indicator | OLED | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 30.88 |
| Support Level | $114.53 | $21.19 |
| Resistance Level | $124.00 | $28.97 |
| Average True Range (ATR) | 2.76 | 1.23 |
| MACD | 0.49 | -0.13 |
| Stochastic Oscillator | 47.52 | 16.97 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.